ASCO News In Brief: Allergan Ligand Retinoid Therapeutics ALRT1057
Allergan Ligand Retinoid Therapeutics ALRT1057: Interim findings of Phase I/II Memorial Sloan-Kettering Cancer Center trial of 9-cis retinoic acid capsules used in the treatment of 15 acute promyelocytic leukemia patients results in 40% complete remission rate for durations of two to 18 months. Unlike ALRT1057, all-trans retinoic acid maintenance therapy for APL often results in retinoid resistance within a few months of treatment, the company said. Irvine, Calif.-based ALRT will begin Phase II/III with ALRT1057 trials this year...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth